Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Non-Current Debt (2009 - 2025)

Grifols' (GIFLF) quarterly Non-Current Debt came in at $10.6 billion in Q4 2025, up 4.34% on a YoY basis from $10.1 billion in Q4 2024, and up 4.34% quarter-over-quarter from $10.1 billion in Q4 2024.

Analysis

Grifols (GIFLF) Non-Current Debt (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Non-Current Debt for 17 consecutive years, with $10.6 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 4.34% year-over-year to $10.6 billion; the trailing twelve-month figure through Dec 2025 stood at $10.6 billion (up 4.34% YoY), and the FY2025 full-year result was $10.3 billion, up 1.27% from the prior year.
  • Non-Current Debt grew to $10.6 billion in Q4 2025 per GIFLF's latest filing, from $10.1 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $10.8 billion in Q4 2023 and bottomed at $8.9 billion in Q4 2021.
  • Historically, Non-Current Debt has averaged $10.1 billion across 5 years, with a median of $10.3 billion in 2022.
  • The sharpest annual moves came in 2022 and 2024: Non-Current Debt grew 15.65% in 2022, then declined 6.05% in 2024.
  • Over 5 years, Non-Current Debt stood at $8.9 billion in 2021, then increased by 15.65% to $10.3 billion in 2022, then grew by 5.03% to $10.8 billion in 2023, then decreased by 6.05% to $10.1 billion in 2024, then advanced by 4.34% to $10.6 billion in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods registered $10.6 billion, $10.1 billion, and $10.8 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 57.30 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 26.25 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn -
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn -
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 7.29 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 10.58 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 10.58 Bn
Dec 31, 2024 10.14 Bn
Dec 31, 2023 10.80 Bn
Dec 31, 2022 10.28 Bn
Dec 31, 2021 8.89 Bn
Dec 31, 2020 7.87 Bn
Sep 30, 2020 7.86 Bn
Mar 31, 2020 7.58 Bn
Dec 31, 2019 7.58 Bn
Sep 30, 2019 7.68 Bn
Dec 31, 2018 6.96 Bn
Sep 30, 2018 7.11 Bn
Jun 30, 2018 7.19 Bn
Mar 31, 2018 8.43 Bn
Dec 31, 2017 6.95 Bn
Jun 30, 2017 6.64 Bn
Dec 31, 2016 5.09 Bn
Sep 30, 2016 5.01 Bn
Jun 30, 2016 5.10 Bn
Mar 31, 2016 4.87 Bn